CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net loss before non-controlling interest	$ (7,555)	$ (13,001)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations	0	234
Stock-based compensation expense	247	784
Depreciation	122	138
Loss on disposal of fixed assets	118	7
Loss on impairment of loans receivable - related party	0	1,985
Accrued interest receivable	0	(39)
Assignment of Medicsight stock to D4D	(4)	0
Gain on sale of loan receivable - related party	(81)	0
Profit on disposal of Medicexchange and other investments	0	(201)
(Increase)/decrease in assets
Accounts receivable	(40)	44
Other receivable - related party	47	57
Prepaid expenses and other current assets	402	(45)
Inventory	(89)	0
Increase/(decrease) in liabilities
Accounts payable	(296)	(170)
Accrued expenses	(421)	(233)
Other payables	(85)	(41)
Net cash used in operating activities	(7,635)	(10,481)
Cash flows from investing activities:
Issuance of Moneygate loans receivable	0	(1,756)
Issuance of Dunamis Capital loans receivable - related party	0	(1,100)
Cash in Medicexchange subsidiaries disposed of	0	(1,101)
Receipt of Dunamis loan repayment	1,100	0
Purchase of fixed assets	(13)	(96)
Receipts from sale of Moneygate	401	0
Receipts of deferred consideration for sale of assets	370	766
Receipts from sale of Medicsight stock	110	0
Net cash provided by/(used in) investing activities	1,968	(3,287)
Cash flows from financing activities:
Sale of common stock, net	639	1,000
Net cash provided by financing activities	639	1,000
Cash flows of discontinued operations:
Net cash used in Medicexchange operating activities	0	(226)
Net cash used in discontinued operations	0	(226)
Effects of exchange rates on cash and cash equivalents	298	(737)
Net change in cash and cash equivalents	(4,730)	(13,731)
Cash and cash equivalents, beginning of year	8,434	22,165
Cash and cash equivalents, end of year	3,704	8,434
Supplemental disclosures of cash paid:
Interest paid	0	0
Taxes paid	$ 0	$ 0